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ABSTRACT  
The management of acute hypoxemic respiratory failure frequently includes the 
use of supraphysiological fractions of inspired oxygen (FiO2), which can be beneficial 
in the short-term but not without risks in the long-term causing acute lung injury (ALI).  
Over the last few years much attention has been focused on the intracellular signalling 
transduction pathways that lead to hyperoxia-induced cell damage, particularly MAP 
kinase cascades. Identification of involved signalling molecules and understanding the 
regulation of the main signal transduction pathways might provide the basis for 
improving the outcome of the patients under high FiO2 through more effective 
therapeutic interventions. This review, which includes studies published from 1987 to 
2015, presents an overview on recent progresses in the hyperoxia ALI field with special 
emphasis to potential therapeutic targets and clinical approaches based on the molecular 
mechanisms underlying hyperoxia-induced inflammation. Further studies are needed to 
gain deeper insight into controversial molecular mechanisms underlying hyperoxia-
induced cell death, which may play a critical role in future pharmacological 
interventions, as well as into hyperoxia-induced cell damage, that could monitor and 
therefore prevent hyperoxia ALI. 
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INTRODUCTION 
The management of acute hypoxemic respiratory failure frequently includes the 
use of supraphysiological oxygen concentrations in inspired air (pO2 (a) > 300 mmHg) 
to ensure adequate blood oxygenation. [1, 2] Although potentially lifesaving in the 
short-term, prolonged hyperoxia is not without risks and has been implicated in organ 
toxicity such as ALI. [3-5] On the one hand, O2 plays a vital role in ATP synthesis, on 
the other hand it is responsible for the production of ROS capable of damaging alveolar 
epithelial cells causing disturbances in pulmonary system and gas exchange impairment. 
There is a narrow margin between therapeutic and deleterious effects of high 
concentrations of inspired oxygen suggesting that the potential benefits and risks of 
ventilation with high FiO2 (0.8–1.0) must be weighed since the question whether 
exposure to supranormal PaO2 is safe in critically ill patients remains unanswered. 
PMNs are the major inflammatory cells involved in the process of ALI, 
generating ROS, leading to alveolar epithelial cells death. [6-9] ROS have been shown 
to participate in the pathogenesis of many human diseases; however, the biochemical 
mechanisms by which ROS cause cell damage and ultimately organ dysfunction are not 
completely understood. [1, 2, 10, 11] Under hyperoxic conditions, excessive ROS act as 
direct cell toxins as well as secondary messengers by inducing the activation of 
intracellular transduction pathways and secretion of proinflammatory cytokines by the 
alveolar epithelial cells. [12] This leads to destruction of the alveolar-capillary barrier, 
increased pulmonary permeability, endothelial and epithelial cell death and PMNs 
influx into alveolar spaces. [12-15] 1 
                                                          
Abbreviations: ALI (acute lung injury); AP-1 (activator protein 1); ATP (adenosine triphosphate); CHI3L (chitinase 3-like 1); DPI 
(diphenyleneiodonium); DUOX (dual oxidase); Egr-1 (early growth response gene-1); ENac (epithelial sodium channel); EP 
(ethylpyruvate); ERK (extracellular signal-regulated kinase); HMGB-1 (high mobility group box-1); HS (hydrogen-rich saline); 
JNK (c-Jun N-terminal kinase); LC3B (protein 1 light chain 3B); MAPK (MAP kinase); MIP-2 (macrophage inflammatory protein-
2); mtALDH (mitochondrial aldeyde dehydrogenase); NF-Κb (nuclear factor Κb); NOX (NADPH oxidase); Nrf2 (nuclear fator-like 
2); PAI-1  (plasminogen activator inhibitor-1); ROS (reactive oxygen species); PKCδ (protein Kinase Cδ); PMNs 
(polymorphonuclear leucocytes); RA (retinoic acid); SP (substance P); TGFβ1 (transforming growth-factor beta-1); TNF-α (tumor 
necrosis factor alpha); Trx (thioredoxin). 
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Over the last few years much attention has been focused on the signalling 
pathways and proinflammatory cytokines that lead to hyperoxia-exposed cells death 
during supplemental oxygen therapy. [16, 17] The comprehension of the molecular 
mechanisms responsible for the development of ALI is based on the identification of 
signaling molecules that are crucial in response to lung injury. A thorough 
understanding into the regulation of the main signal transduction pathways that can lead 
to alveolar epithelial cell injury after prolonged hyperoxia might provide the basis for 
improving the outcome of the patients under high FiO2 through more effective 
therapeutic interventions.  
The purpose of this review is to provide a critical evaluation of the recent 
bibliography on hyperoxia ALI, focusing on recently described intracellular molecular 
pathways and exploring potential therapeutic targets and future clinical applications. 
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METHODS 
Eligible studies were identified by an electronic search of PubMed, involving 
studies published from 1987 to 2015. The sensitive search strategy combined the 
following keywords: molecular mechanisms; hyperoxia; and acute lung injury. All 
articles and cross-referenced studies from retrieved articles were screened for pertinent 
information and reviewed by both Authors. Inclusion criteria consisted in experimental 
and systematic review articles, published as original studies, with available abstract. 
Publications not written in English were excluded. 
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SIGNAL TRANSDUCTION PATHWAYS 
ROS generated by NOX family enzymes play a pivotal role in hyperoxia-
induced ALI. [2, 13] Although the effect of ROS in ALI has not been completely 
defined, previous studies demonstrated direct pulmonary cells injury through lipid 
peroxidation, enzyme inactivation, DNA damage, and cellular reducing agents decrease. 
[18] Distinct NOX enzymes, may specifically activate a range of different signaling 
pathways by modulating their subcellular location, expression level and interaction with 
membrane proteins. [18-22] However, previous studies have reported NOX1 as the 
main participant member of NOX family in ALI by stimulating ROS generation and cell 
death in lung epithelium and endothelium, whether NOX2 and NOX4 induce cell 
migration and cell death, although controversy exists. [22-24]  
DUOXs are major NOX homologues and a significant source of ROS in lung 
epithelium. [2] Previous studies have suggested that DUOX-generated ROS play a 
central role in the regulation of innate immune responses and modulation of cell death 
in airway epithelial cells exposed to prolonged hyperoxia, rather than NOX1. [2, 18, 25]  
Generation of ROS under supraphysiological concentrations of oxygen is 
reported to be one of the main damaging stimuli that can induce or mediate 
phosphorylation of MAPK signal transduction pathways by altering the structure and 
function of signaling proteins through modification of critical aminoacid residues. [19, 
26, 27] MAPK signal transduction pathways regulate a wide range of vital cellular 
mechanisms, such as cell growth, proliferation, differentiation, stress responses, and 
ultimately survival and apoptosis through modulation of distinct intracellular and 
nuclear substrates. [28, 29] To date, several studies described four distinct MAPK 
cascades: ERK 1/2, JNK, p38 and ERK 5. [28]  
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Hyperoxia-induced ROS, together with NOX1 activation, are responsible for the 
triggering of ERK 1/2 pathway characterized by the activation of a wide range of 
substrates in distinct locations, particularly the nucleus (fig. 1).  [28, 30] In addition to 
direct interaction between ROS and ERK 1/2, ROS are responsible for decreasing 
mtALDH activity and stimulating CHI3L. [28]  As a defense mechanism against the 
damaging effects induced by hyperoxia, phosphorylated ERK 1/2 pathway promotes 
survival genes transcription, such as Egr-1, Nrf2, and AP-1. [28] Between the survival 
genes transcripted in the ERK 1/2 signaling pathway, previous studies demonstrated 
that decreased transcription of Nrf2 promotes increased ALI and mortality through 
suppressed expression of several antioxidant enzymes and superoxide dismutase, which 
are involved in cellular protection against hyperoxia-induced inflammation. [2, 20, 30] 
Although most studies describe ERK 1/2 cascade as pro-survival signal transduction 
pathway in hyperoxia-exposed cells, additional reports have mentioned alveolar 
macrophage apoptosis under other conditions that can be ascribed to the specific cell 
type involved. [10, 27] Thus, in hyperoxic conditions, ERK 1/2 phosphorylation might 
have a dual role as either promoter or inhibitor of apoptosis, and these roles appear 
depend on the cell type and culture conditions. [31] 
 As a key member of the MAPK family, JNK activation in hyperoxia-exposed 
cells is induced by ROS and NOX1 (fig. 2). [19] Once activated, JNK induces 
phosphorylation of several substrates located in the cytoplasm and nucleus promoting 
transcription of apoptotic genes as well as immune and stress responses. [28] Several 
studies have reported AP-1 complex as a major target of phosphorylated JNK. [28] 
Activated in several mechanisms, including oxidant signaling, immune responses, and 
cell differentiation and apoptosis, AP-1 complex has been shown to play an important 
role in modulating both cell proliferation and death in a cell-type and stimulus-
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dependent manner. [29, 32] However, Romashko et al. demonstrated that sustained 
activation of AP-1 is more closely associated with apoptosis. [32] Together with AP-1 
complex, TGFβ1 is involved in inflammation and hyperoxia-induced cell death as well 
as impaired alveolarization. [33] Although the final effect of JNK activation supports 
necrosis and apoptosis, Porzionato et al. suggested that JNK phosphorylation might 
stimulate pro-survival mediators such as microtubule-associated LC3B. [28] Thus, in 
hyperoxia-exposed cells, the effect of JNK pathway activation is distinct, depending on 
the stimuli and strength as well as duration of phosphorylation, and can range from 
apoptosis to increased survival. [28, 34] Most studies propose JNK as a pro-apoptotic 
factor; however a protective role of JNK activation in response to hyperoxia has already 
been described. [35] 
 Similar to other members of MAPK family, p38 activation caused by stress 
stimuli and signals transmitted through the recruitment of specific receptors, plays an 
important role in hyperoxia-induced lung injury (fig. 3). [28, 32] Li et al. reported p38 
has a central regulator of immunological effects, cell apoptosis, senescence, and 
survival as well as cell-cycle checkpoints. [34] Apart from direct activation from ROS, 
p38 activity is stimulated by ROS-induced PKCδ and CH3IL. [28] To date, p38 
activation role in ALI is variable. Further analysis will be needed to identify the 
contributing factors for the variability of p38 activation under hyperoxic conditions. The 
role of p38 activation in hyperoxia-exposed cell and consequent lung damage is yet 
unclear, while some reports have described protective effects, most studies have 
reported detrimental actions. [36, 37] 
 Under hyperoxic conditions, ROS-mediated cell death is partially dependent on 
caspase-mediated signaling pathways (fig. 4). [19, 29] Hyperoxia-induced activation of 
signal transduction pathways leads to either necrosis or apoptosis. [14, 38, 39] Indeed, 
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both mechanisms can co-exist, once they share similar induction agents in similar cell 
types. [32, 38] ROS induce death receptor Fas activation with resultant stimulation of 
initiator caspase 8. [10] This triggers a range of events as activation of Bax, Bid, Bim 
and Back which increase PKCδ expression. [10] As an apoptotic modulator, PKCδ 
stimulates cleavage of executioner caspases 3 and 9, culminating in cell death by 
apoptosis and/or necrosis. [10] Caspase 3 is considered the most important of the 
effector caspases. [40] The main role of apoptosis in epithelial damage under hyperoxic 
conditions remains unclear, however several mechanisms underlying hyperoxia-induced 
cell death have already been proposed. [41] 
 Pro-inflammatory cytokines have been implicated in mediating neutrophil influx 
into hyperoxic lungs; however, molecular processes underlying PMNs recruitment 
remain unclear. [10, 40] Such pro-inflammatory cytokines, including TNF-α, MIP-2, 
PAI-1, IL-1β, IL-6 and IL-8, are crucial mediators in the early stages of inflammatory 
response. [1, 42] The transcriptional factor NF-κB is often described as the factor 
required for maximal expression of numerous cytokines implicated in the HALI. [32, 
40] Entezari et al. determined that hyperoxia-exposed cell injury is characterized by 
increased extracellular HMGB-1 production. [9] A DNA-binding protein, extracellular 
HMGB-1 triggers an overwhelming late inflammatory response that promotes the 
progression of ALI. [43-46] Indeed, extracellular HMGB-1 promotes the release of 
cytokines such has IL-1β, TNF-α, MIP-2 and macrophage migration inhibitory factor, 
and conversely, cytokines control further release of HMGB-1 to both plasma and lung 
epithelial lining fluids. [9] 
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POTENTIAL THERAPEUTIC TARGETS 
Understanding the molecular mechanisms may be useful for the identification of 
potential therapeutic targets as well as biomarkers to be monitored in the course of 
HALI (Table 1).  
Regarding the described role of DUOX 2 in lung injury after prolonged 
hyperoxia, Kim et al. reported that an acute reduction of DUOX 2 expression is 
sufficient to inhibit ALI and consequent cell death. [2] Simultaneously, Xu et al. 
demonstrated that the overexpression of mtALDH attenuates hyperoxia-induced cell 
death by inducing ERK 1/2 phosphorylation, and inhibition of ERK 1/2 cascade 
partially suppresses the positive effect of mtALDH, reporting ERK 1/2 activation 
through mtALDH as a defense mechanism against hyperoxia. [47] As well as mtALDH 
overexpression, CHI3L knock-down, and increased survival genes transcription has 
been shown to play a protective role from hyperoxia-induced apoptosis by increasing 
ERK 1/2 phosphorylation. [28, 48] In addition, Kim et al. demonstrated increased 
survival in CHI3L-deficient cells through p38 attenuation. [48] These findings may 
prove helpful in developing potential therapies based on DUOX 2 specific inhibitors in 
the treatment of ALI. 
JNK cascade exposure to supranormal concentrations of O2 activates 
morphological and biochemical markers, such as LC3B. [49]  Tanaka et al. reported that 
LC3B overexpression confers cytoprotection against hyperoxia injury through 
autophagy stimulation and inhibition of caspase-3 cleavage. [28, 49] Meanwhile, several 
studies described the selective inhibition of p38 as a sufficient mechanism to increase 
cell survival in hyperoxic-exposed cells. [36, 37] 
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CLINICAL IMPLICATIONS 
Over the last few years, much progress has been made in developing possible 
therapeutic strategies involved in hyperoxia-induced ALI (table 2). Regarding the 
described role of NOX enzymes, their inhibition may have significant effect in 
improving therapies to alleviate hyperoxia-induced lung damage through suppression of 
endothelial and epithelial cell death. Papaiahgari et al. demonstrated that inhibition of 
NOX by DPI considerably reduces the generation of intracellular and extracellular ROS, 
suggesting that NOX actively contributes to the conversion of oxygen into O2
− and its 
inhibition may be helpful as a potential therapeutic target for ALI by reducing oxidative 
stress induced by hyperoxia. [2, 30] 
Porzionato et al. have identified numerous exogenous stimulators of MAPK 
family members as protective modulators of hyperoxic stimuli. [28] Incubation or 
administration of hyperoxia-exposed cells with ATP, inosine and laminin substrates 
results in increased survival cell response through ERK 1/2 phosphorylation. [28] 
Ahmad et al. demonstrated that ATP release and subsequent ATP-mediated signaling 
events are vital for cell survival in hyperoxia. [50] In addition, Buckley et al. described 
the protective role of inosine treatment during hyperoxic exposure. [51] Meanwhile, 
Buckley et al. also demonstrated that culture of cells on laminin substrates, with respect 
to other plastic supports, resulted in increased phosphorylation of ERK 1/2. [52] Huan 
et al. added that the addition of SP to cell cultures can promote proliferation and inhibit 
apoptosis by suppressing JNK and p38 signal pathways after hyperoxia exposure, which 
attenuates induced oxidative lung injury. [53, 54] In addition, Li et al. and Chen et al. 
reported ERK 1/2, JNK and p38 significant increase under prolonged hyperoxic 
conditions. [55, 56] Additional studies demonstrated that RA and Trx treatment induced 
JNK and p38 decline and ERK 1/2 further elevation. [55, 56]  
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Sureshbabu et al. have reported TGFβ1 as a critical mediator of ALI. [33] 
Indeed, Tamarapu et al. described TGFβ1 as a modulator of ENac that reduces its 
expression, and alveolar sodium transport in epithelial cells. [57] The inhibitory effect 
of TGFβ1 on ENac, the main determinant of alveolar fluid clearance across the alveolar 
epithelium, is mediated by ERK 1/2 cascade activation. [57] The same study has 
identified serotonin as an endogenous inhibitor of ENac through TGFβ1 expression 
stimulation. [57] Therefore, miR-16, as a molecule that regulates serotonin system and 
upregulates ENac should be considered as a potential therapeutic approach to modulate 
ENac expression and restore alveolar fluid balance in ALI. [57] 
Regarding p38 cascade, once activated by oxidative stress, PKCδ has been 
reported as an important apoptosis modulator through increased production of the 
caspase-induced PKCδ cleavage products. [28] Interestingly, Grinnell et al. 
demonstrated that PKCδ chemical inhibitor (rottlerin) significantly attenuated p38 
activation as well as apoptosis, suggesting a potential dual role for PKCδ in ROS-
induced apoptosis. [28, 58] As mentioned, rottlerin acts as an upstream regulator of p38 
activation and as an inducer of DNA damage, through its caspase-3-dependent cleavage 
fragment, what may prove helpful in developing future therapies based on PKCδ 
chemical inhibitors in the treatment of ALI. [58] Simultaneously, Otterbein et al. 
reported the protective role of low concentration CO in hyperoxic lung injury, extending 
survival and exerting potent anti-inflammatory effects with reduced inflammatory cell 
influx into the lungs and marked attenuation in the expression of pro-inflammatory 
cytokines. [59] Indeed, exogenous administration of CO limits the progress of 
histopathological changes and attenuates cytokine expression induced by hyperoxia. 
[28, 59] 
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  Xie et al. demonstrated decreased caspase 3 activity after H2 or HS treatment, 
suggesting a preventing role of H2 treatment in lung cell apoptosis. [40] The same study 
added that the effective therapeutic role of H2 or HS in hyperoxia-induced ALI also 
occurred through downregulation of inflammation and apoptosis via suppressing NF-κB 
activation. [40] Most of the data suggested endogenous NO, similarly to H2, exerts an 
effective therapeutic role in many disorders including oxygen toxicity through 
decreasing oxidative stress, inflammation, and apoptosis, although controversy exists. 
[10, 40] 
Entezari et al. suggested a link between extracellular HMGB-1 and ALI 
pathogenesis once low levels of extracellular HMGB-1 decreased inflammation. [9] In 
addition, they have shown that inhibition of HMGB-1 by neutralizing anti-HMGB-1 
antibodies and small molecule EP significantly protects lung tissue against hyperoxia-
induced extracellular HMGB-1. [9] In addition, heparin was shown to modulate 
infiltration of neutrophils and improve gas exchange. [1] Thus, Li et al. demonstrated 
that pharmacological inhibition with enoxaparine reduced HMGB-1 and PAI-1 
production during prolonged hyperoxia. [1] 
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CONCLUSION 
The present review focused on recent progresses in the ALI field with special 
emphasis to molecular mechanisms underlying hyperoxia-induced inflammation after 
high FiO2 ventilation. The wide involvement of signal transduction pathways in lung 
responses to hyperoxia suggests their modulation may have significant effect in 
improving therapies to alleviate ALI in patients on oxygen therapy through suppression 
of endothelial and epithelial cell death. In summary, further analysis is needed to gain 
deeper insight into controversial molecular mechanisms underlying hyperoxia-induced 
cell death which may play critical role in future pharmaceutical interventions as well as 
biomarkers monitoring targeted at prevention or resolution of ALI. 
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Table 1. Overview of therapeutic targets in hyperoxia-induced ALI.  
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Reference Year Model Molecule Mechanism Role in ALI 
[2] 2014 Mice DUOX 2 ERK 1/2 and JNK phosphorylation Deleterious 
[28] 2015 Mice Survival genes ERK 1/2 phosphorylation Protector 
[47] 2006 Mice mtALDH ERK 1/2 phosphorylation Protector 
[48] 2012 Mice CH3IL ERK 1/2 phosphorylation and p38 
inhibition 
Deleterious 
[49] 2012 Mice LC3B autophagy stimulation and caspase-3 
cleavage inhibition 
Protector 
25 
Table 2. Overview of potential pharmacological treatments oh hyperoxia-induced ALI. 
Reference Year Model Mechanism Future therapy 
[1] 2011 Mice PAI-1 and HMGB-1 
inhibition 
Enoxaparin 
[9] 2014 Mice HMGB-1 inhibition Anti-HMGB-1 
and EP 
[40] 2012 Mice Caspase 3/9 and NfκB 
inhibition 
H2 and HS 
[50] 2004 Mice ERK 1/2 phosphorylation ATP 
[51] 2005 Mice ERK 1/2 phosphorylation Inosine 
[52] 1999 Mice ERK 1/2 phosphorylation Laminin 
substrates 
[53] 2009 Mice JNK and p38 inhibition SP 
[55] 2006 Mice ERK 1/2 phosphorylation 
JNK and p38 inhibition 
RA 
[56] 2010 Mice JNK and p38 inhibition Trx 
[59] 2015 Mice p38 inhibition CO 
[30] 2004 Mice NOX inhibition DPI 
[58] 2012 Mice PKCδ inhibition rottlerin 
[57] 2012 Mice TGFβ1 inhibition miR-16 
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FIGURE LEGENDS: 
 
Figure 1. Schematic diagram of the extracelular signal-regulated kinase (ERK) 
signaling pathway in lung cells exposed to prolonged hyperoxia: supraphysiological 
oxygen concentrations in inspired air can lead to reactive oxygen species (ROS) 
production via NADPH oxidase (NOX) phosphorylation. ROS promote stimulation of 
mitochondrial aldeyde dehydrogenase (mtALDH) and chitinase 3-like 1 (CHI3L), and 
cause DNA damage. The signal is also transduced to small GTP-binding proteins (Ras),  
which in turn activate the core unit of the cascade composed of a MAPKKK (Raf), a 
MAPKK (MEK1/2), and MAPK (Erk). Activated ERK leads to transcription of survival 
genes, like activator protein 1 (AP-1), early growth response gene-1 (Egr-1), nuclear 
factor-like 2 (Nrf2), which inhibit necrotic and apoptotic cell death. In contrast, ERK 
activation might induce apoptosis/necrosis of alveolar macrophages. 
 
Figure 2. Schematic diagram of the c-Jun N-terminal kinase (JNK) signaling pathway 
in lung cells exposed to prolonged hyperoxia: supraphysiological oxygen concentrations 
in inspired air can lead to reactive oxygen species (ROS) production via NADPH 
oxidase (NOX) phosphorylation. ROS stimulate JNK activation through the membrane 
proximal kinase MAPKKK, typically MEKK1–4, that phosphorylates and activates 
MKK4 or MKK7, the JNK kinases. Once phosphorylated, JNK promotes inflammation 
and impaired alveolarization through induction of activator protein 1 (AP-1) and 
transforming growth factor-beta 1 (TGFβ1), respectively. Thus, the final effect of JNK 
activation supports necrosis and apoptosis. JNK might stimulate microtubule associated 
protein 1 light chain 3B (LC3B) factor, which would induce autophagic mechanisms to 
protect the cell against hyperoxia. 
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Figure 3. Schematic diagram of the p38 signaling pathway in lung cells exposed to 
prolonged hyperoxia: supraphysiological oxygen concentrations in inspired air can lead 
to reactive oxygen species (ROS) production, via NADPH oxidase (NOX) 
phosphorylation. ROS induce p38 activation through protein kinase Cδ (PKCδ), 
chitinase 3-like 1 (CHI3L), and also MAPKKK, typically MEKK 1 to 4 or a mixed 
lineage kinase (MLK) 2 or 3, that phosphorylate and activate MKK3 or 6, the p38 
MAPK kinases. Once activated, p38 supports necrosis and apoptosis.  
 
Figure 4. Schematic diagram of the apoptosis/necrosis signaling pathway in lung cells 
exposed to prolonged hyperoxia: supraphysiological oxygen concentrations in inspired 
air can lead to Fas receptor phosphorylation and further activation of caspase 8, which 
induces the activation of the pro-apoptotic proteins Bax, Bid, Bim and Back, resulting 
in increased protein kinase Cδ (PKCδ) expression. Once activated, PKCδ stimulates 
caspases 3 and 9, culminating in cell death by necrosis or apoptosis. 
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single file at the revision stage.
• Please note that individual figure files larger than 10 MB must be provided in separate source files.
A detailed guide on electronic artwork is available on our website:
https://www.elsevier.com/artworkinstructions.
You are urged to visit this site; some excerpts from the detailed information are given here.
Formats
Regardless of the application used, when your electronic artwork is finalized, please 'save as' or
convert the images to one of the following formats (note the resolution requirements for line drawings,
halftones, and line/halftone combinations given below):
EPS (or PDF): Vector drawings. Embed the font or save the text as 'graphics'.
TIFF (or JPG): Color or grayscale photographs (halftones): always use a minimum of 300 dpi.
TIFF (or JPG): Bitmapped line drawings: use a minimum of 1000 dpi.
TIFF (or JPG): Combinations bitmapped line/half-tone (color or grayscale): a minimum of 500 dpi
is required.
Please do not:
• Supply files that are optimized for screen use (e.g., GIF, BMP, PICT, WPG); the resolution is too low.
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• Supply files that are too low in resolution.
• Submit graphics that are disproportionately large for the content.
Color artwork
Please make sure that artwork files are in an acceptable format (TIFF (or JPEG), EPS (or PDF), or
MS Office files) and with the correct resolution. If, together with your accepted article, you submit
usable color figures then Elsevier will ensure, at no additional charge, that these figures will appear
in color online (e.g., ScienceDirect and other sites) regardless of whether or not these illustrations
are reproduced in color in the printed version. For color reproduction in print, you will receive
information regarding the costs from Elsevier after receipt of your accepted article. Please
indicate your preference for color: in print or online only. For further information on the preparation
of electronic artwork, please see https://www.elsevier.com/artworkinstructions.
Illustration services
Elsevier's WebShop (http://webshop.elsevier.com/illustrationservices) offers Illustration Services
to authors preparing to submit a manuscript but concerned about the quality of the images
accompanying their article. Elsevier's expert illustrators can produce scientific, technical and medical-
style images, as well as a full range of charts, tables and graphs. Image 'polishing' is also available,
where our illustrators take your image(s) and improve them to a professional standard. Please visit
the website to find out more.
Figure captions
Ensure that each illustration has a caption. A caption should comprise a brief title (not on the figure
itself) and a description of the illustration. Keep text in the illustrations themselves to a minimum but
explain all symbols and abbreviations used.
Tables
Please submit tables as editable text and not as images. Tables can be placed either next to the
relevant text in the article, or on separate page(s) at the end. Number tables consecutively in
accordance with their appearance in the text and place any table notes below the table body. Be
sparing in the use of tables and ensure that the data presented in them do not duplicate results
described elsewhere in the article. Please avoid using vertical rules.
References
Citation in text
Please ensure that every reference cited in the text is also present in the reference list (and vice
versa). Any references cited in the abstract must be given in full. Unpublished results and personal
communications are not recommended in the reference list, but may be mentioned in the text. If these
references are included in the reference list they should follow the standard reference style of the
journal and should include a substitution of the publication date with either 'Unpublished results' or
'Personal communication'. Citation of a reference as 'in press' implies that the item has been accepted
for publication.
Reference links
Increased discoverability of research and high quality peer review are ensured by online links to
the sources cited. In order to allow us to create links to abstracting and indexing services, such as
Scopus, CrossRef and PubMed, please ensure that data provided in the references are correct. Please
note that incorrect surnames, journal/book titles, publication year and pagination may prevent link
creation. When copying references, please be careful as they may already contain errors. Use of the
DOI is encouraged.
Web references
As a minimum, the full URL should be given and the date when the reference was last accessed. Any
further information, if known (DOI, author names, dates, reference to a source publication, etc.),
should also be given. Web references can be listed separately (e.g., after the reference list) under a
different heading if desired, or can be included in the reference list.
Reference management software
Most Elsevier journals have their reference template available in many of the
most popular reference management software products. These include all products
that support Citation Style Language styles (http://citationstyles.org), such as Mendeley
(http://www.mendeley.com/features/reference-manager) and Zotero (https://www.zotero.org/), as
well as EndNote (http://endnote.com/downloads/styles). Using the word processor plug-ins from
these products, authors only need to select the appropriate journal template when preparing their
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article, after which citations and bibliographies will be automatically formatted in the journal's style.
If no template is yet available for this journal, please follow the format of the sample references and
citations as shown in this Guide.
Users of Mendeley Desktop can easily install the reference style for this journal by clicking the following
link:
http://open.mendeley.com/use-citation-style/respiratory-medicine
When preparing your manuscript, you will then be able to select this style using the Mendeley plug-
ins for Microsoft Word or LibreOffice.
Reference formatting
There are no strict requirements on reference formatting at submission. References can be in any style
or format as long as the style is consistent. Where applicable, author(s) name(s), journal title/book
title, chapter title/article title, year of publication, volume number/book chapter and the pagination
must be present. Use of DOI is highly encouraged. The reference style used by the journal will be
applied to the accepted article by Elsevier at the proof stage. Note that missing data will be highlighted
at proof stage for the author to correct. If you do wish to format the references yourself they should
be arranged according to the following examples:
Reference style
Text: Indicate references by number(s) in square brackets in line with the text. The actual authors
can be referred to, but the reference number(s) must always be given.
Example: '..... as demonstrated [3,6]. Barnaby and Jones [8] obtained a different result ....'
List: Number the references (numbers in square brackets) in the list in the order in which they appear
in the text.
Examples:
Reference to a journal publication:
[1] J. van der Geer, J.A.J. Hanraads, R.A. Lupton, The art of writing a scientific article, J. Sci. Commun.
163 (2010) 51–59.
Reference to a book:
[2] W. Strunk Jr., E.B. White, The Elements of Style, fourth ed., Longman, New York, 2000.
Reference to a chapter in an edited book:
[3] G.R. Mettam, L.B. Adams, How to prepare an electronic version of your article, in: B.S. Jones, R.Z.
Smith (Eds.), Introduction to the Electronic Age, E-Publishing Inc., New York, 2009, pp. 281–304.
Reference to a website:
[4] Cancer Research UK, Cancer statistics reports for the UK. http://www.cancerresearchuk.org/
aboutcancer/statistics/cancerstatsreport/, 2003 (accessed 13.03.03).
Journal abbreviations source
Journal names should be abbreviated according to the List of Title Word Abbreviations:
http://www.issn.org/services/online-services/access-to-the-ltwa/.
Video data
Elsevier accepts video material and animation sequences to support and enhance your scientific
research. Authors who have video or animation files that they wish to submit with their article are
strongly encouraged to include links to these within the body of the article. This can be done in the
same way as a figure or table by referring to the video or animation content and noting in the body
text where it should be placed. All submitted files should be properly labeled so that they directly
relate to the video file's content. In order to ensure that your video or animation material is directly
usable, please provide the files in one of our recommended file formats with a preferred maximum
size of 150 MB. Video and animation files supplied will be published online in the electronic version
of your article in Elsevier Web products, including ScienceDirect: http://www.sciencedirect.com.
Please supply 'stills' with your files: you can choose any frame from the video or animation or
make a separate image. These will be used instead of standard icons and will personalize the
link to your video data. For more detailed instructions please visit our video instruction pages at
https://www.elsevier.com/artworkinstructions. Note: since video and animation cannot be embedded
in the print version of the journal, please provide text for both the electronic and the print version
for the portions of the article that refer to this content.
AudioSlides
The journal encourages authors to create an AudioSlides presentation with their published article.
AudioSlides are brief, webinar-style presentations that are shown next to the online article on
ScienceDirect. This gives authors the opportunity to summarize their research in their own words and
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to help readers understand what the paper is about. More information and examples are available at
https://www.elsevier.com/audioslides. Authors of this journal will automatically receive an invitation
e-mail to create an AudioSlides presentation after acceptance of their paper.
Supplementary material
Supplementary material can support and enhance your scientific research. Supplementary files
offer the author additional possibilities to publish supporting applications, high-resolution images,
background datasets, sound clips and more. Please note that such items are published online exactly
as they are submitted; there is no typesetting involved (supplementary data supplied as an Excel
file or as a PowerPoint slide will appear as such online). Please submit the material together with the
article and supply a concise and descriptive caption for each file. If you wish to make any changes to
supplementary data during any stage of the process, then please make sure to provide an updated
file, and do not annotate any corrections on a previous version. Please also make sure to switch
off the 'Track Changes' option in any Microsoft Office files as these will appear in the published
supplementary file(s). For more detailed instructions please visit our artwork instruction pages at
https://www.elsevier.com/artworkinstructions.
Submission checklist
The following list will be useful during the final checking of an article prior to sending it to the journal
for review. Please consult this Guide for Authors for further details of any item.
Ensure that the following items are present:
One author has been designated as the corresponding author with contact details:
• E-mail address
• Full postal address
All necessary files have been uploaded, and contain:
• Keywords
• All figure captions
• All tables (including title, description, footnotes)
Further considerations
• Manuscript has been 'spell-checked' and 'grammar-checked'
• All references mentioned in the Reference list are cited in the text, and vice versa
• Permission has been obtained for use of copyrighted material from other sources (including the
Internet)
Printed version of figures (if applicable) in color or black-and-white
• Indicate clearly whether or not color or black-and-white in print is required.
For any further information please visit our customer support site at http://support.elsevier.com.
AFTER ACCEPTANCE
Use of the Digital Object Identifier
The Digital Object Identifier (DOI) may be used to cite and link to electronic documents. The DOI
consists of a unique alpha-numeric character string which is assigned to a document by the publisher
upon the initial electronic publication. The assigned DOI never changes. Therefore, it is an ideal
medium for citing a document, particularly 'Articles in press' because they have not yet received their
full bibliographic information. Example of a correctly given DOI (in URL format; here an article in the
journal Physics Letters B):
http://dx.doi.org/10.1016/j.physletb.2010.09.059
When you use a DOI to create links to documents on the web, the DOIs are guaranteed never to
change.
Online proof correction
Corresponding authors will receive an e-mail with a link to our online proofing system, allowing
annotation and correction of proofs online. The environment is similar to MS Word: in addition to
editing text, you can also comment on figures/tables and answer questions from the Copy Editor.
Web-based proofing provides a faster and less error-prone process by allowing you to directly type
your corrections, eliminating the potential introduction of errors.
If preferred, you can still choose to annotate and upload your edits on the PDF version. All instructions
for proofing will be given in the e-mail we send to authors, including alternative methods to the online
version and PDF.
We will do everything possible to get your article published quickly and accurately. Please use this
proof only for checking the typesetting, editing, completeness and correctness of the text, tables and
figures. Significant changes to the article as accepted for publication will only be considered at this
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stage with permission from the Editor. It is important to ensure that all corrections are sent back
to us in one communication. Please check carefully before replying, as inclusion of any subsequent
corrections cannot be guaranteed. Proofreading is solely your responsibility.
Offprints
The corresponding author, at no cost, will be provided with a personalized link providing 50
days free access to the final published version of the article on ScienceDirect. This link can
also be used for sharing via email and social networks. For an extra charge, paper offprints
can be ordered via the offprint order form which is sent once the article is accepted for
publication. Both corresponding and co-authors may order offprints at any time via Elsevier's
WebShop (http://webshop.elsevier.com/myarticleservices/offprints). Authors requiring printed copies
of multiple articles may use Elsevier WebShop's 'Create Your Own Book' service to collate multiple
articles within a single cover (http://webshop.elsevier.com/myarticleservices/booklets).
AUTHOR INQUIRIES
You can track your submitted article at https://www.elsevier.com/track-submission. You can track
your accepted article at https://www.elsevier.com/trackarticle. You are also welcome to contact
Customer Support via http://support.elsevier.com.
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